Table 4.
Outcome of TP53-mutated myeloid malignancy patients after allogeneic stem cell transplantation. AML: Acute Myeloid Leukemia, CR: Complete Remission, EFS: Event Free Survival, MAC: Myeloablative Conditioning, MDS, Myelodysplastic Syndrome, OS: Overall Survival, PFS: Progression Free Survival, RIC: Reduced Intensity Conditioning.
| Pathology | N | Conditioning | RFS | OS | NRM | Reference |
|---|---|---|---|---|---|---|
| AML (62%)/MDS (38%) with 17p abnormalities | 30 | RIC (63%)/MAC (37%) | Median RFS: 6 months (AML)–4 months (MDS) | Median OS: 18 months (AML)–11 months (MDS) | 9.1% (MDS)–10.6% (AML) | [67] |
| AML with 17p abnormalities | 139 | RIC (59%)/MAC (41%) | 2 years LFS: 24% | 2 years OS: 28% | 2 years NRM: 15% | [68] |
| TP53 mut MDS | 289 | RIC/MAC | Not available | 3 years OS: 20% Median OS: 8 months |
2 years NRM: 35% | [69] |
| TP53 mut AML/MDS | 83 | RIC (29%)/MAC (79%) | 1 year PFS: 25% Median PFS: 5 months |
1 year OS: 35% Median OS: 8 months |
1 year NRM: 20% | [70] |